acalabrutinib
Showing 1 - 25 of 69
Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
Acalabrutinib in Chronic Lymphocytic Leukaemia in United Kingdom
Recruiting
- Chronic Lymphocytic Leukemia, CLL
- Acalabrutinib
-
Aylesbury, United Kingdom
- +7 more
Jan 12, 2023
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)
Recruiting
- Central Nervous System Lymphoma
- Acalabrutinib
- Isavuconazole
-
Chapel Hill, North Carolina
- +1 more
Mar 24, 2022
Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)
Withdrawn
- Chronic Lymphocytic Leukemia
- CLL/SLL
- Acalabrutinib
-
New York, New YorkWeill Cornell Medicine
Mar 25, 2022
Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)
Recruiting
- Food Allergy
- Food Allergy Peanut
- Acalabrutinib
-
Baltimore, MarylandJohns Hopkins Bayview Medical Center
Dec 30, 2021
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Feb 2, 2022
Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)
Not yet recruiting
- Lymphoma
- Mantle Cell Lymphoma
- Acalabrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 2, 2022
Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)
Recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- Durvalumab
- Acalabrutinib
-
Saint Louis, MissouriWashington University School of Medicine
Mar 14, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- Venetoclax
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 20, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Rochester (Acalabrutinib, Rituximab)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Acalabrutinib
- Rituximab
-
Rochester, New YorkUniversity of Rochester
Feb 7, 2022
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in
Recruiting
- Autoimmune Hemolytic Anemia
- +3 more
- Acalabrutinib
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 9, 2022
Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- R-CHOP chemotherapy
-
Vancouver, British Columbia, Canada
- +3 more
Mar 17, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 13, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- Acalabrutinib
- Duvelisib
- (no location specified)
Jun 2, 2022
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Mantle Cell Lymphoma Trial in New York (Acalabrutinib, Lenalidomide, Rituximab)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
New York, New YorkWeill Cornell Medicine
Oct 29, 2021
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Healthy Volunteers Trial in Tempe (Acalabrutinib, Fluconazole, Isavuconazole)
Completed
- Healthy Volunteers
- Acalabrutinib
- +2 more
-
Tempe, ArizonaCelerion
Nov 17, 2021